MVCD5
MCID: MCR115
MIFTS: 65

Microvascular Complications of Diabetes 5 (MVCD5)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 5

MalaCards integrated aliases for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 57 73 12 36 38
Diabetic Retinopathy 11 53 43 14 16 71 75 31 33
Microvascular Complications of Diabetes, Susceptibility to, 5 57 28 5
Retinopathy, Diabetic 57 75
Diabetic Nephropathy 73 71
Mvcd5 57 73
Retinopathy, Diabetic, Susceptibility to 57
Retinal Abnormality - Diabetes-Related 11

Classifications:



External Ids:

Disease Ontology 11 DOID:8947
OMIM® 57 612633
OMIM Phenotypic Series 57 PS603933
ICD9CM 34 362.0
NCIt 49 C34538
SNOMED-CT 68 154678005
ICD10 31 H36.0
MedGen 40 C2674665
UMLS 71 C0011881 C0011884

Summaries for Microvascular Complications of Diabetes 5

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to microvascular complications of diabetes 1 and type 1 diabetes mellitus. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Mecobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include Eye, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia: 75 Diabetic retinopathy (also known as diabetic eye disease), is a medical condition in which damage occurs... more...

More information from OMIM: 612633 PS603933

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1021)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.9 VEGFA SERPINF1 INS IGF1 ICAM1 FLT1
2 type 1 diabetes mellitus 32.6 VEGFA PON1 INS IGF1 ICAM1 ALB
3 diabetic angiopathy 32.4 VEGFA NOS3 INS ICAM1 ALB AGER
4 microvascular complications of diabetes 3 32.3 INS ALB AKR1B1 AGER ACE
5 retinal detachment 32.3 VEGFA SERPINF1 IGF1 ICAM1 FGF2
6 type 2 diabetes mellitus 32.2 VEGFA SERPINE1 PRKCB PON1 PGF NOS3
7 macular holes 32.0 VEGFA SERPINF1 ANGPT2
8 retinal disease 32.0 VEGFA PON1 INS ALB
9 cataract 31.8 VEGFA SERPINF1 PON1 INS IGF1 ICAM1
10 retinal ischemia 31.8 VEGFA PGF KDR ICAM1 FGF2
11 retinal vascular disease 31.7 VEGFA TEK SERPINF1 PGF NOS3 KDR
12 leukostasis 31.7 VEGFA SERPINF1 KDR ICAM1 AGER
13 rubeosis iridis 31.7 VEGFA PGF INS
14 vitreous detachment 31.7 VEGFA PGF FGF2
15 lipid metabolism disorder 31.7 SERPINE1 PON1 NOS3 INS IGF1 ICAM1
16 retinal vein occlusion 31.5 VEGFA SERPINF1 SERPINE1 KDR ANGPT2 ACE
17 eye disease 31.5 VEGFA TEK SERPINF1 PGF NOS3 KDR
18 kidney hypertrophy 31.5 NOS3 INS ALB ACE
19 insulin-like growth factor i 31.4 VEGFA INS IGF1 FGF2
20 endophthalmitis 31.4 VEGFA PGF ICAM1 FLT1 ALB
21 hypoglycemia 31.4 VEGFA INS IGF1 ALB AKR1B1 ACE
22 diabetic neuropathy 31.4 VEGFA PRKCB PON1 INS ALB AKR1B1
23 autonomic neuropathy 31.4 INS ALB AKR1B1
24 hypercholesterolemia, familial, 1 31.3 NOS3 INS ACE
25 coronary heart disease 1 31.3 SERPINE1 PON1 INS ACE
26 henoch-schoenlein purpura 31.3 ICAM1 ALB ACE
27 hyperhomocysteinemia 31.3 SERPINE1 PON1 NOS3 ALB
28 familial hyperlipidemia 31.3 SERPINE1 PON1 INS ACE
29 chronic kidney disease 31.3 PON1 NOS3 INS IGF1 ALB ACE
30 vascular disease 31.3 VEGFA TEK SERPINE1 PON1 NOS3 KDR
31 peripheral nervous system disease 31.2 VEGFA KDR INS IGF1 ICAM1 FGF2
32 optic nerve disease 31.2 VEGFA INS ALB ACE
33 hypertensive nephropathy 31.2 ALB ACE
34 retinal microaneurysm 31.1 VEGFA INS AKR1B1
35 keratopathy 31.1 VEGFA IGF1 AKR1B1
36 arteries, anomalies of 31.1 VEGFA NOS3 INS ALB ACE
37 atherosclerosis susceptibility 31.1 SERPINE1 PON1 NOS3 INS ICAM1 ALB
38 deficiency anemia 31.1 VEGFA PON1 INS IGF1 ALB ACE
39 urinary tract infection 31.1 INS ALB ACE
40 cerebrovascular disease 31.1 PON1 INS ALB ACE
41 central retinal vein occlusion 31.1 VEGFA PGF KDR ICAM1 FLT1
42 apnea, obstructive sleep 31.1 VEGFA NOS3 INS IGF1 ICAM1 ALB
43 gestational diabetes 31.1 PGF NOS3 INS IGF1 FLT1
44 cardiovascular system disease 31.1 SERPINE1 PON1 NOS3 INS IGF1 ICAM1
45 hypothyroidism 31.1 VEGFA SERPINE1 PON1 INS IGF1 ALB
46 kidney disease 31.0 VEGFA SERPINE1 PRKCB PON1 NOS3 INS
47 sleep apnea 31.0 VEGFA SERPINE1 NOS3 INS IGF1 ICAM1
48 peripheral artery disease 31.0 VEGFA NOS3 INS ICAM1 ALB ACE
49 peripheral vascular disease 31.0 VEGFA SERPINE1 PGF NOS3 KDR INS
50 ischemia 31.0 VEGFA TEK PON1 PGF NOS3 KDR

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM®:

612633 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 ACE AGER AKR1B1 ALB ANGPT2 FGF2
2 cardiovascular system MP:0005385 10.36 ACE AGER ALB ANGPT2 FGF2 FLT1
3 nervous system MP:0003631 10.3 FGF2 FLT1 ICAM1 IGF1 INS KDR
4 muscle MP:0005369 10.27 AGER ALB FGF2 FLT1 ICAM1 IGF1
5 growth/size/body region MP:0005378 10.27 ACE AGER AKR1B1 FLT1 ICAM1 IGF1
6 cellular MP:0005384 10.25 ACE AGER ALB ANGPT2 FGF2 FLT1
7 immune system MP:0005387 10.24 ACE AGER ALB ANGPT2 FLT1 ICAM1
8 normal MP:0002873 10.19 AGER ALB FLT1 IGF1 INS KDR
9 renal/urinary system MP:0005367 10.16 ACE AGER AKR1B1 ALB IGF1 INS
10 neoplasm MP:0002006 10.15 ACE ALB FGF2 ICAM1 IGF1 PGF
11 vision/eye MP:0005391 10.03 AKR1B1 ANGPT2 FGF2 FLT1 ICAM1 INS
12 hematopoietic system MP:0005397 10.03 ACE AGER ANGPT2 FGF2 FLT1 ICAM1
13 skeleton MP:0005390 10.02 AGER AKR1B1 FGF2 IGF1 INS KDR
14 mortality/aging MP:0010768 9.8 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
15 integument MP:0010771 9.32 AGER ANGPT2 ICAM1 IGF1 INS KDR

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 433)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
5
Captopril Approved Phase 4 62571-86-2 44093
6
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
7
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
8
Candesartan cilexetil Approved Phase 4 145040-37-5
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
12
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
13
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Carbamide peroxide Approved Phase 4 124-43-6
16
Simvastatin Approved Phase 4 79902-63-9 54454
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Povidone-iodine Approved Phase 4 25655-41-8
19
Iodine Approved, Investigational Phase 4 7553-56-2 807
20
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
21
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
22
Insulin glargine Approved Phase 4 160337-95-1 118984454
23
Amlodipine Approved Phase 4 88150-42-9 2162
24
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
25
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
26
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Doxazosin Approved Phase 4 74191-85-8 3157
29
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
30
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
31
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
34
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
35
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
36
Allopurinol Approved Phase 4 315-30-0 2094 135401907
37
Nisoldipine Approved Phase 4 63675-72-9 4499
38
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
39
Probucol Approved, Investigational Phase 4 23288-49-5 4912
40
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
41
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
42
Atorvastatin Approved Phase 4 134523-00-5 60823
43
Indapamide Approved Phase 4 26807-65-8 3702
44
Insulin lispro Approved Phase 4 133107-64-9 16132438
45
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
46
Trandolapril Approved Phase 4 87679-37-6 5484727
47
Saxagliptin Approved Phase 4 361442-04-8 11243969
48
Ranibizumab Approved Phase 4 347396-82-1
49 Grape Approved Phase 4
50
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501

Interventional clinical trials:

(show top 50) (show all 902)
# Name Status NCT ID Phase Drugs
1 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
2 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
4 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Unknown status NCT04283162 Phase 4 Calcium Dobesilate
5 Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients Unknown status NCT04140201 Phase 4 Simvastatin 40mg;Fenofibrate 200mg;Omega 3 fatty acid
6 DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery Unknown status NCT04362241 Phase 4 Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
7 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
8 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
9 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Unknown status NCT04464694 Phase 4 Ranibizumab
10 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
11 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
12 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
15 Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD) Unknown status NCT04215445 Phase 4 Empagliflozin 25 MG
16 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
17 Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY) Unknown status NCT04038125 Phase 4 Ozurdex Drug Implant Product
18 Prospective Trial of Dexamethasone implAnt for Treatment Naïve diabeTic Macular Edema: The Multicenter DANTE Study Unknown status NCT04448496 Phase 4 Dexamethasone implant
19 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
20 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
21 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
22 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
23 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
24 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
25 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
26 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
27 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
28 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
29 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Completed NCT02096874 Phase 4 Bevacizumab
30 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
31 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
32 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
33 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
34 Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed NCT00174824 Phase 4 Insulin glargine
35 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
36 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
37 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
38 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
39 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Completed NCT02874313 Phase 4 Pharmacological treatment
40 Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. Completed NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
41 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
42 A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study) Completed NCT04619303 Phase 4 Dexamethasone intravitreal implant;Bevacizumab Injectable Product
43 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
44 Yellow Micropulse Laser 577-nm vs Infrared Diode Micropulse Laser 810-nm for the Treatment of Diabetic Macular Edema Completed NCT04359771 Phase 4
45 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
46 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Completed NCT02559180 Phase 4 aflibercept
47 20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study Completed NCT00411970 Phase 4
48 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
49 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Completed NCT02432547 Phase 4 Aflibercept
50 Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) Completed NCT04018482 Phase 4

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 5 28 PON1

Anatomical Context for Microvascular Complications of Diabetes 5

Organs/tissues related to Microvascular Complications of Diabetes 5:

MalaCards : Eye, Retina, Bone Marrow, Endothelial, Kidney, Bone, Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Affected by disease, potential therapeutic candidate
2 Eye Outer Nuclear Layer Mature M Cone Cells Affected by disease, potential therapeutic candidate
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Affected by disease, potential therapeutic candidate
5 Eye Outer Nuclear Layer Mature S Cone Cells Affected by disease, potential therapeutic candidate

Publications for Microvascular Complications of Diabetes 5

Articles related to Microvascular Complications of Diabetes 5:

(show top 50) (show all 47384)
# Title Authors PMID Year
1
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 53 62 57 5
11918623 2002
2
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 53 62 57 5
9661650 1998
3
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 57 5
11335891 2001
4
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 5
11889198 2002
5
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 5
11788650 2002
6
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 5
9011577 1997
7
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. 53 62
20166888 2010
8
Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. 53 62
20225131 2010
9
Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. 53 62
19216096 2010
10
Expression of stromal cell-derived factor-1 in diabetic retinopathy. 53 62
20497701 2010
11
Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy. 53 62
20373882 2010
12
Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. 53 62
19238311 2010
13
Protein kinase C beta (PRKCB1) and pigment epithelium derived factor (PEDF) gene polymorphisms and diabetic retinopathy in a south Indian cohort. 53 62
20141354 2010
14
Diabetic retinopathy: An update on treatment. 53 62
20193825 2010
15
Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. 53 62
20088710 2010
16
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. 53 62
20008515 2010
17
Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. 53 62
20142713 2010
18
Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. 53 62
19926157 2010
19
Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism). 53 62
19882513 2010
20
The anti-angiogenic isoforms of VEGF in health and disease. 53 62
19909248 2009
21
Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. 53 62
19752172 2009
22
Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. 53 62
19553626 2009
23
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 53 62
19646547 2009
24
Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. 53 62
19709741 2009
25
Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. 53 62
19628492 2009
26
Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. 53 62
19838431 2009
27
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. 53 62
19526210 2009
28
Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. 53 62
19784389 2009
29
A systematic meta-analysis of genetic association studies for diabetic retinopathy. 53 62
19587357 2009
30
Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes. 53 62
19304585 2009
31
Specific medical intervention for diabetic retinopathy. 53 62
19380207 2009
32
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor. 53 62
19445630 2009
33
Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea. 53 62
19538247 2009
34
Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. 53 62
19419896 2009
35
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. 53 62
19254713 2009
36
Treating diabetic retinopathy by inhibiting growth factor pathways. 53 62
19337953 2009
37
Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. 53 62
19263526 2009
38
Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. 53 62
19262488 2009
39
Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. 53 62
19365032 2009
40
Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. 53 62
19217457 2009
41
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. 53 62
18974200 2009
42
[Role of vascular endothelial growth factor in the pathogenesis of diabetic retinopathy]. 53 62
19517837 2009
43
Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. 53 62
19232015 2009
44
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. 53 62
18709380 2009
45
Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration. 53 62
19223990 2009
46
[Proliferative diabetic retinopathy inauguring gestational diabetes]. 53 62
18514611 2008
47
Regulation of pigment epithelium-derived factor production and release by retinal glial (Müller) cells under hypoxia. 53 62
18676622 2008
48
Vasoinhibins: novel inhibitors of ocular angiogenesis. 53 62
18544641 2008
49
[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus]. 53 62
18830032 2008
50
Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. 53 62
18791689 2008

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PON1 NM_000446.7(PON1):c.163T>A (p.Leu55Met) SNV Risk Factor
13736 rs854560 GRCh37: 7:94946084-94946084
GRCh38: 7:95316772-95316772

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TEK PRKCB PGF KDR IGF1
2 13.78 FGF2 FLT1 IGF1 INS KDR NOS3
3
Show member pathways
13.71 FGF2 FLT1 IGF1 KDR NOS3 PGF
4
Show member pathways
13.64 VEGFA TEK SERPINF1 PRKCB NOS3 KDR
5
Show member pathways
13.57 TEK PRKCB PGF NOS3 KDR IGF1
6
Show member pathways
13.55 VEGFA TEK PGF KDR INS IGF1
7
Show member pathways
13.42 TEK PRKCB PGF NOS3 KDR IGF1
8
Show member pathways
13.33 TEK PRKCB PGF KDR IGF1 FLT1
9
Show member pathways
13.32 TEK PRKCB PGF KDR IGF1 FLT1
10
Show member pathways
13.31 VEGFA TEK SERPINE1 PRKCB NOS3 IGF1
11
Show member pathways
13.24 VEGFA TEK PRKCB PGF NOS3 KDR
12
Show member pathways
13.08 FGF2 FLT1 IGF1 KDR PGF PRKCB
13
Show member pathways
13.03 PRKCB PGF KDR INS IGF1 FLT1
14
Show member pathways
12.73 PRKCB PGF KDR IGF1 FLT1 FGF2
15
Show member pathways
12.72 VEGFA PRKCB KDR IGF1 FGF2
16 12.69 VEGFA PRKCB PGF NOS3 KDR INS
17
Show member pathways
12.66 ANGPT2 FGF2 FLT1 IGF1 INS KDR
18
Show member pathways
12.65 FGF2 FLT1 IGF1 KDR PGF PRKCB
19
Show member pathways
12.5 VEGFA PRKCB NOS3 KDR ICAM1
20
Show member pathways
12.47 VEGFA PRKCB PGF NOS3 KDR FLT1
21
Show member pathways
12.44 PRKCB NOS3 KDR FLT1
22
Show member pathways
12.44 ICAM1 KDR NOS3 PRKCB VEGFA
23
Show member pathways
12.42 TEK PGF KDR IGF1 FLT1 FGF2
24
Show member pathways
12.4 VEGFA KDR FLT1 FGF2
25
Show member pathways
12.3 VEGFA PRKCB PGF NOS3 KDR FLT1
26 12.27 VEGFA PRKCB PGF KDR IGF1 FLT1
27 12.26 TEK PRKCB KDR FLT1
28
Show member pathways
12.19 VEGFA PRKCB NOS3 KDR FLT1 FGF2
29 12.15 TEK KDR FLT1 FGF2 ANGPT2
30
Show member pathways
12.14 VEGFA PRKCB NOS3 KDR
31 12.01 VEGFA KDR INS IGF1 FGF2 ALB
32 11.98 VEGFA TEK SERPINF1 PGF KDR INS
33 11.88 INS IGF1 FGF2
34
Show member pathways
11.86 TEK KDR FLT1
35 11.83 VEGFA KDR FLT1
36
Show member pathways
11.83 PRKCB NOS3 KDR FLT1
37 11.79 FGF2 IGF1 VEGFA
38 11.79 ANGPT2 FGF2 FLT1 KDR NOS3 TEK
39 11.65 VEGFA PRKCB NOS3 KDR FLT1
40 11.64 VEGFA KDR FGF2
41 11.63 KDR NOS3 TEK VEGFA
42 11.62 KDR INS IGF1 FGF2
43 11.6 VEGFA KDR FLT1
44 11.56 VEGFA KDR FGF2
45 11.56 VEGFA INS IGF1 FGF2
46
Show member pathways
11.52 VEGFA KDR INS
47 11.49 FGF2 FLT1 KDR VEGFA
48 11.42 VEGFA SERPINE1 ANGPT2
49 11.3 FLT1 KDR SERPINE1 VEGFA
50 11.29 VEGFA SERPINF1 PRKCB

GO Terms for Microvascular Complications of Diabetes 5

Cellular components related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.12 ACE AGER ALB ANGPT2 FGF2 FLT1
2 extracellular space GO:0005615 9.77 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
3 platelet alpha granule lumen GO:0031093 9.76 VEGFA SERPINE1 IGF1 ALB

Biological processes related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.46 VEGFA TEK KDR IGF1 ALB AKR1B1
2 positive regulation of cell population proliferation GO:0008284 10.44 FGF2 FLT1 IGF1 INS KDR PGF
3 positive regulation of cell migration GO:0030335 10.35 FLT1 IGF1 INS KDR VEGFA
4 positive regulation of protein phosphorylation GO:0001934 10.29 AGER FGF2 KDR PGF TEK VEGFA
5 negative regulation of gene expression GO:0010629 10.28 ACE FGF2 IGF1 INS KDR SERPINF1
6 response to hypoxia GO:0001666 10.27 ACE AGER ANGPT2 PGF VEGFA
7 positive regulation of protein kinase B signaling GO:0051897 10.19 VEGFA TEK INS IGF1 FGF2
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.18 AGER FGF2 ICAM1 IGF1 KDR TEK
9 positive regulation of cell division GO:0051781 10.16 VEGFA PGF FGF2
10 positive regulation of endothelial cell migration GO:0010595 10.16 VEGFA TEK KDR FGF2
11 positive chemotaxis GO:0050918 10.15 VEGFA PGF FGF2
12 cellular response to amyloid-beta GO:1904646 10.15 IGF1 ICAM1 AGER
13 animal organ regeneration GO:0031100 10.14 PGF ANGPT2 ACE
14 positive regulation of blood vessel endothelial cell migration GO:0043536 10.13 FGF2 KDR NOS3 VEGFA
15 positive regulation of epithelial cell proliferation GO:0050679 10.12 VEGFA KDR IGF1 FGF2
16 sprouting angiogenesis GO:0002040 10.11 VEGFA TEK PGF
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 10.1 TEK FLT1 FGF2
18 negative regulation of endothelial cell apoptotic process GO:2000352 10.1 TEK SERPINE1 KDR ICAM1
19 positive regulation of endothelial cell proliferation GO:0001938 10.1 VEGFA TEK PGF KDR FGF2
20 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.09 VEGFA KDR FLT1
21 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 10.09 SERPINE1 NOS3 ICAM1
22 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 10.08 VEGFA KDR FGF2
23 positive regulation of focal adhesion assembly GO:0051894 10.08 VEGFA TEK KDR
24 lung development GO:0030324 10.08 ACE FGF2 KDR NOS3 VEGFA
25 positive regulation of MAPK cascade GO:0043410 10.07 VEGFA TEK KDR INS IGF1 FLT1
26 cell migration involved in sprouting angiogenesis GO:0002042 10.06 VEGFA KDR FGF2
27 vascular endothelial growth factor receptor signaling pathway GO:0048010 10.06 VEGFA PGF KDR FLT1
28 angiogenesis GO:0001525 10.06 ANGPT2 FGF2 FLT1 KDR NOS3 PGF
29 induction of positive chemotaxis GO:0050930 10.02 AGER PGF VEGFA
30 positive regulation of mast cell chemotaxis GO:0060754 9.98 VEGFA PGF
31 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.97 KDR VEGFA
32 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.96 KDR VEGFA
33 glomerulus vasculature development GO:0072012 9.95 TEK ANGPT2
34 angiogenesis involved in coronary vascular morphogenesis GO:0060978 9.94 FGF2 ACE
35 Tie signaling pathway GO:0048014 9.94 TEK ANGPT2
36 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.93 ACE VEGFA
37 vascular endothelial growth factor signaling pathway GO:0038084 9.92 VEGFA PGF KDR FLT1
38 positive regulation of epithelial tube formation GO:1905278 9.83 VEGFA FGF2
39 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 FGF2 FLT1 IGF1 INS KDR TEK
40 positive regulation of angiogenesis GO:0045766 9.62 VEGFA TEK SERPINE1 PRKCB PGF NOS3

Molecular functions related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor activity GO:0005021 9.46 KDR FLT1
2 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA PGF
3 chemoattractant activity GO:0042056 9.1 VEGFA PGF FGF2

Sources for Microvascular Complications of Diabetes 5

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....